Adial Pharmaceuticals Inc (ADIL) — Cash Flow-to-Debt Ratio
Latest as of March 2026:
-1.07x
Adial Pharmaceuticals Inc (ADIL) has a Cash Flow-to-Debt Ratio of -1.07x as of March 2026, meaning its operating cash flow of $-1.61 Million could theoretically repay -1% of its total liabilities ($1.51 Million) in one year. See how financially flexible is Adial Pharmaceuticals Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-1.07x
Operating CF / Total Liabilities
Operating Cash Flow
$-1.61 Million
USD
Total Liabilities
$1.51 Million
USD
Data as of
Mar 2026
Most recent filing
Adial Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Adial Pharmaceuticals Inc across 11 annual periods. For the full cash flow conversion analysis, see Adial Pharmaceuticals Inc (ADIL) cash conversion ratio.
Annual Cash Flow-to-Debt Ratio for Adial Pharmaceuticals Inc (2015–2025)
Year-by-year debt coverage analysis for Adial Pharmaceuticals Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.27x | $-6.49 Million | $1.52 Million | ▲ +39.9% |
| 2024 | -7.09x | $-6.92 Million | $975.86K | ▲ +31.9% |
| 2023 | -10.42x | $-6.81 Million | $653.51K | ▼ -128.7% |
| 2022 | -4.55x | $-11.19 Million | $2.46 Million | ▼ -57.2% |
| 2021 | -2.90x | $-11.95 Million | $4.13 Million | ▲ +42.9% |
| 2020 | -5.07x | $-7.63 Million | $1.51 Million | ▲ +56.9% |
| 2019 | -11.76x | $-6.34 Million | $539.05K | ▼ -21.4% |
| 2018 | -9.68x | $-2.50 Million | $257.97K | ▼ -1919.9% |
| 2017 | -0.48x | $-494.86K | $1.03 Million | ▲ +55.4% |
| 2016 | -1.08x | $-274.38K | $255.02K | ▲ +87.7% |
| 2015 | -8.76x | $-465.22K | $53.08K | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.